Features of the Course of Radioinduced Breast Cancer. Clinical Observation

Author:

Zamilov M. M.1ORCID,Menshikov K. V.2ORCID,Musin Sh. I.2ORCID,Sultanbaev A. V.1ORCID,Zamilova G. I.3ORCID,Nguyen A. H.1ORCID

Affiliation:

1. Republican Clinical Oncology Dispensary

2. Republican Clinical Oncology Dispensary; Bashkir State Medical University

3. Bashkir State Medical University

Abstract

Introduction. Hodgkin’s lymphoma is most commonly reported in the young age of 20 to 40 years. Radiation therapy remained the first-choice option before the advent of modern chemotherapy agents. Thereafter, the risk of radioinduced breast cancer after radiotherapy with total radiation dose of 38 Gy or more increased 4.5-fold.Materials and methods. The presented clinical case demonstrates aggressive breast cancer that developed 43 years after radiation therapy for Hodgkin's lymphoma.Results and discussion. In the 1990s, chemotherapy regimens for Hodgkin’s lymphoma were not effective enough to control the disease, therefore, radiotherapy was an indispensable measure. Secondary radioinduced tumors take the second place (26 %) in the structure of mortality from Hodgkin’s lymphoma. The emergence of new, more effective chemotherapy regimens reduced the risk of secondary tumors and, in particular, breast cancer.Conclusion. At present, up to 75 % of patients with Hodgkin’s lymphoma can be cured using modern methods of chemotherapy and radiation therapy. In follow-up care, it is necessary to consider the high risk of secondary malignant neoplasms, especially lung and breast cancer.

Publisher

Bashkir State Medical University

Subject

General Engineering,Energy Engineering and Power Technology

Reference15 articles.

1. Abshire D., Lang M.K. The evolution of radiation therapy in treating cancer. Semin Oncol Nurs. 2018;34(2):151–7. DOI: 10.1016/j.soncn.2018.03.006

2. Datsenko P.V., Pan’shin G.A. Thirty-year results of radiotherapy and СОРР (МОРР) protocol for Hodgkin’s lymphoma. P.A. Herzen Journal of Oncology. 2014;3(4):30–7 (In Russ.).

3. Mauch P.M., Kalish L.A., Marcus K.C., Shulman L.N., Krill E., Tarbell N.J., et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995;1(1):33–42. PMID: 9166452

4. Hodgson D.C., Gilbert E.S., Dores G.M., Schonfeld S.J., Lynch C.F., Storm H., et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25(12):1489–97. DOI: 10.1200/JCO.2006.09.0936

5. Menshikov K.V., Pushkarev A.V., Sultanbaev A.V., Pushkarev V.A., Sharifgaliev I.A. Radiogenic vaginal angiosarcoma: a clinical case. Creative surgery and oncology. 2020;10(2):143–8 (In Russ.). DOI: 10.24060/2076-3093-2020-10-2-143-148

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3